Bristol-Myers Squibb Co. (BMY)

45.86
0.18 0.39
NYSE : Health Technology
Prev Close 45.68
Open 45.81
Day Low/High 45.69 / 46.56
52 Wk Low/High 44.30 / 63.69
Volume 15.27M
Avg Volume 14.69M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 80.71B
EPS 3.00
P/E Ratio 15.71
Div & Yield 1.64 (3.31%)
Jim Cramer: Bristol-Myers Needs to Slim Down

Jim Cramer: Bristol-Myers Needs to Slim Down

Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.

Dow May Linger at 20K for a While

Dow May Linger at 20K for a While

I am reluctant to call this a breakout, and am willing to sit back and wait.

Bristol-Myers numbers cut at BMO

Synergy Pharmaceuticals Consolidating Recent Gains

The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb is one reason the sector is not participating, as its key oncology drug Opdivo wil...

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer looks at Bristol-Myers Squibb's Opdivo setback.

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers.

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

Bristol-Myers upgraded at Jefferies

December Trades Bring Eggnog, Mistletoe -- and Some Coal

December Trades Bring Eggnog, Mistletoe -- and Some Coal

A couple of quick wins, a hedge/fade that didn't work, and 2 triggers not firing.

Cramer: If You Can Make Sense of Today's Market, Let Me Know

Cramer: If You Can Make Sense of Today's Market, Let Me Know

It's the most random day of the week, with stocks all over the map.

Will Stock No Longer Be Bristol-Mired?

Will Stock No Longer Be Bristol-Mired?

It's finally seeing a little light and is still worth owning.

Citi Healthcare Conf.

My Takeaways and Observations

What a strange day -- maybe even ominous.   This table tells it all.    The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...

Is Bristol-Myers Feeling Better? Not Really

Is Bristol-Myers Feeling Better? Not Really

The stock will eventually rebase, but we don't know where or when.

My Takeaways and Observations (3:30 p.m. Edition)

It may be time to embrace the contrary.    First issue (!!): The Palm Beach Chronicles.   My weekly (brief) technical review of the markets -- cooling off ahead?    BTIG's Stockton is bullish and so, as I have expressed, are most others!   Campbell ...

The Good, the Bad and the Ugly (2:30 PM Edition)

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...

How to Be a Smarter Biotech Investor

How to Be a Smarter Biotech Investor

Interpreting "K-M curves" correctly is an important tool for biotech investors.

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Bullish and Bearish Chart Reversals

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

Credit Suisse Healthcare Conf.

My Takeaways and Observations

"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax.   A consecutive nine-day market drop was snapped as we regained most that was lost in that period.   Today was a great day. (Boy, would I like to annualize the pe...

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Credibility Is a Precious Market Commodity

Cramer: Credibility Is a Precious Market Commodity

And if it's lost, good luck getting it back.

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.